Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 928

Sort by

Sort Order Select

Journal Articles

Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells

Diana Hanekamp, Lok Lam Ngai, Jeroen J. W. M. Janssen, Arjan van de Loosdrecht, Gert J. Ossenkoppele, Jacqueline Cloos

Blood (2021) 137 (12): 1694–1697.

https://doi.org/10.1182/blood.2020007150

Published: 2021

Includes: Supplemental data

Journal Articles

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Blood (2021) 137 (8): 1019–1023.

https://doi.org/10.1182/blood.2020008164

Published: 2021

Includes: Supplemental data

Journal Articles

DARTs point the way forward in AML

Saar Gill

Blood (2021) 137 (6): 720–721.

https://doi.org/10.1182/blood.2020009020

Published: 2021

Journal Articles

How I diagnose and treat NPM1 -mutated AML

Brunangelo Falini, Lorenzo Brunetti, Maria Paola Martelli

Blood (2021) 137 (5): 589–599.

https://doi.org/10.1182/blood.2020008211

Published: 2021

Journal Articles

Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia

Robert P. Hasserjian, David P. Steensma, Timothy A. Graubert, Benjamin L. Ebert

Blood (2020) 135 (20): 1729–1738.

https://doi.org/10.1182/blood.2019004770

Published: 2020

Journal Articles

How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation

Alexandros Spyridonidis

Blood (2020) 135 (19): 1639–1649.

https://doi.org/10.1182/blood.2019003566

Published: 2020

Journal Articles

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Blood (2020) 135 (9): 680–688.

https://doi.org/10.1182/blood.2019002959

Published: 2020

Includes: Supplemental data

Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Blood (2019) 134 (Supplement_2): LBA-3.

https://doi.org/10.1182/blood-2019-132405

Published: 2019

Journal Articles

Flowsom: An R-Based Evaluation Strategy for Flow Cytometry-Based Measurable Residual Disease (MRD) Diagnostics in Acute Myeloid Leukemia (AML)

Veit Bücklein, MD, Alexandra Stein, Benjamin Tast, PhD, Thomas Koehnke, MD, Karsten Spiekermann, MD, Francis Lacombe, MD PhD, Marion Subklewe, MD

Blood (2019) 134 (Supplement_1): 4656.

https://doi.org/10.1182/blood-2019-129866

Published: 2019

Journal Articles

Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Correlation with Outcomes in Plasma Cell and Lymphoid Malignancies

Mohammad O Hussaini, MD, Jaya Srivastava, PhD, Lik Wee Lee, PhD, Taiga Nishihori, MD, Bijal Shah, MD, Melissa Alsina, MD, Rachid Baz, MD, Javier Pinilla Ibarz, MD PhD, Kenneth H. Shain, MD PhD

Blood (2019) 134 (Supplement_1): 4654.

https://doi.org/10.1182/blood-2019-129846

Published: 2019

Journal Articles

Complemental Prognostic Impact of Flow Cytometric and Molecular Quantification of Minimal/Measurable Residual Disease in Acute Myeloid Leukemia

Wolfgang Kern, MD, Manja Meggendorfer, PhD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_1): 4657.

https://doi.org/10.1182/blood-2019-130304

Published: 2019

Journal Articles

Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

Selina M. Luger, MD FRCPC, Zhuoxin Sun, PhD, Sanam Loghavi, MD, Hillard M Lazarus, MD, Jacob M. Rowe, MB, BS, Martin S. Tallman, MD, Keith W. Pratz, MD, Mark Litzow, MD

Blood (2019) 134 (Supplement_1): 1309.

https://doi.org/10.1182/blood-2019-128377

Published: 2019

Journal Articles

Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy

Blood (2019) 134 (Supplement_1): 735.

https://doi.org/10.1182/blood-2019-122779

Published: 2019

Journal Articles

Anti-CD19 CAR T Therapy Following Autologous HSCT May be Safe and Effective in Patients with Refractory Large B-Cell Lymphoma

Wei Liu, Wenyang Huang, Rui Lv, Shuhui Deng, MD, Shuhua Yi, MD, Lugui Qiu, MD PhD, Dehui Zou, MD

Blood (2019) 134 (Supplement_1): 784.

https://doi.org/10.1182/blood-2019-127659

Published: 2019

Journal Articles

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Luciano J. Costa, MD PhD, Saurabh Chhabra, MD, Kelly N. Godby, MD, Eva Medvedova, MD, Robert F. Cornell, MD MS, Aric C. Hall, MD, Rebecca W. Silbermann, MD, Racquel Innis-Shelton, MD, Binod Dhakal, MBBS, Diego DeIdiaquez, MD, Pamela Hardwick, RN, Yelak Biru, James L. Omel, MD, Parameswaran Hari, MBBS, MD, Natalie Scott Callander, MD

Blood (2019) 134 (Supplement_1): 860.

https://doi.org/10.1182/blood-2019-123170

Published: 2019

Journal Articles

Comparative Study of Tumor Biopsy and Ctdna to Support Patient Selection in Phase I Trials: The Gustave Roussy Single Center Experience in Aggressive B-Cell Lymphomas

Anthony Tarabay, MD, Jean-Marie Michot, MD, Anne Aupérin, Julien Lazarovici, Julien Rossignol, MD PhD, David Ghez, MD PhD, Peggy Dartigues-Cuillères, MD, Veronique Vergé, Vincent Ribrag, MD, Christophe Massard, Valérie Camara-clayette

Blood (2019) 134 (Supplement_1): 1496.

https://doi.org/10.1182/blood-2019-127170

Published: 2019

Journal Articles

Clinical Application of Circulating Tumor DNA in Plasma of Patients with Primary Central Nervous System Lymphoma

Sang Eun Yoon, Won Seog Kim, MD PhD, Seok Jin Kim, MD PhD, Young Hyeh Ko, MD, Kim Yeon Jeong, PhD, Park Donghyun, PhD

Blood (2019) 134 (Supplement_1): 1491.

https://doi.org/10.1182/blood-2019-130075

Published: 2019

Journal Articles

A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

Andrew Kent, MD PhD, Sumithira Vasu, MDMBBS, Derek Schatz, Natalie Monson, Steven Devine, MD, Clayton Smith, MD, Jonathan A Gutman, MD, Daniel A Pollyea, MD

Blood (2019) 134 (Supplement_1): 1311.

https://doi.org/10.1182/blood-2019-127418

Published: 2019

Journal Articles

Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients

Elizabeth A. Griffiths, MD, Hagop M. Kantarjian, MD, Casey L. O'Connell, MD, Karen W.L. Yee, MD, Wendy Stock, MD, Naval G. Daver, MD, Elias Jabbour, MD, Ellen K. Ritchie, MD, Jean-Pierre Issa, MD, Katherine J. Walsh, MD, David A. Rizzieri, MD, Scott D. Lunin, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 1319.

https://doi.org/10.1182/blood-2019-131394

Published: 2019

Journal Articles

Durable Responses and Survival in High Risk AML and MDS Patients Treated with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Luca L.G. Janssen, MD, Theresia M. Westers, PhD, Jeroen Rovers, MD PhD, Peter Valk, PhD, Jacqueline Cloos, PhD, Tanja D. de Gruijl, PhD, Arjan A. Van de Loosdrecht, MD PhD

Blood (2019) 134 (Supplement_1): 1381.

https://doi.org/10.1182/blood-2019-127881

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

DARTs point the way forward in AML

How I diagnose and treat NPM1 -mutated AML

Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia

How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Flowsom: An R-Based Evaluation Strategy for Flow Cytometry-Based Measurable Residual Disease (MRD) Diagnostics in Acute Myeloid Leukemia (AML)

Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Correlation with Outcomes in Plasma Cell and Lymphoid Malignancies

Complemental Prognostic Impact of Flow Cytometric and Molecular Quantification of Minimal/Measurable Residual Disease in Acute Myeloid Leukemia

Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy

Anti-CD19 CAR T Therapy Following Autologous HSCT May be Safe and Effective in Patients with Refractory Large B-Cell Lymphoma

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Comparative Study of Tumor Biopsy and Ctdna to Support Patient Selection in Phase I Trials: The Gustave Roussy Single Center Experience in Aggressive B-Cell Lymphomas

Clinical Application of Circulating Tumor DNA in Plasma of Patients with Primary Central Nervous System Lymphoma

A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients

Durable Responses and Survival in High Risk AML and MDS Patients Treated with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only